Scholarlink

Clinical issue <p>CAR-T&#xa0;cell therapy is complex and is now offered at a&#xa0;growing number of oncology centers in Germany. In addition to the initial CAR-T&#xa0;cell treatment, several advances and complementary therapies are available, which radiologists should be familiar with to properly evaluate treatment response and detect side effects early.</p> Standard treatment <p>In hemato-oncologic diseases, combinations of chemotherapy and targeted therapies are usually administered.</p> Treatment innovations <p>CAR-T-cell therapy combined with complementary immunotherapies.</p> Diagnostic work-up <p>For current indications, cross-sectional imaging—typically positron emission tomography/computed tomography—is used for staging and for evaluating therapy response.</p> Performance <p>The response rate is approximately 66.4% (25.5–90.9%).</p> Achievements <p>CAR-T&#xa0;cell therapy represents a&#xa0;new era in immunotherapy, and its recent advances mark a&#xa0;significant innovation in oncologic treatment.</p> Practical recommendations <p>Radiologists should understand the principles of CAR-T&#xa0;cell therapy in order to accurately assess treatment response and recognize early signs of potential side effects.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Übersicht zu CAR-T-Zell-Therapien

  • 期刊论文

  • 发表日期：

    2025年12月9日

查看全文
  • Mirjam Gerwing,
  • Michel Eisenblätter

摘要

Clinical issue

CAR-T cell therapy is complex and is now offered at a growing number of oncology centers in Germany. In addition to the initial CAR-T cell treatment, several advances and complementary therapies are available, which radiologists should be familiar with to properly evaluate treatment response and detect side effects early.

Standard treatment

In hemato-oncologic diseases, combinations of chemotherapy and targeted therapies are usually administered.

Treatment innovations

CAR-T-cell therapy combined with complementary immunotherapies.

Diagnostic work-up

For current indications, cross-sectional imaging—typically positron emission tomography/computed tomography—is used for staging and for evaluating therapy response.

Performance

The response rate is approximately 66.4% (25.5–90.9%).

Achievements

CAR-T cell therapy represents a new era in immunotherapy, and its recent advances mark a significant innovation in oncologic treatment.

Practical recommendations

Radiologists should understand the principles of CAR-T cell therapy in order to accurately assess treatment response and recognize early signs of potential side effects.